About viking therapeutics inc. - VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
VKTX At a Glance
Viking Therapeutics, Inc.
9920 Pacific Heights Boulevard
San Diego, California 92121
| Phone | 1-858-704-4660 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -359,639,000.00 | |
| Sector | Health Technology | Employees | 53 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
VKTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 6.319 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.292 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
VKTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -6,785,641.509 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VKTX Liquidity
| Current Ratio | 9.334 |
| Quick Ratio | 9.334 |
| Cash Ratio | 9.205 |
VKTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -44.289 |
| Return on Equity | -47.341 |
| Return on Total Capital | -56.264 |
| Return on Invested Capital | -47.322 |
VKTX Capital Structure
| Total Debt to Total Equity | 0.021 |
| Total Debt to Total Capital | 0.021 |
| Total Debt to Total Assets | 0.019 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |